{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:13:41Z","timestamp":1787318021859,"version":"build-2736575974"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-21779-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:49:28Z","timestamp":1761752968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Applicability of phase 3 trial selection criteria to real-world transthyretin amyloid cardiomyopathy patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Michael","family":"Poledniczek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena Marie","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kronberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Ermolaev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rettl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Camuz Ligios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Nitsche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Badr Eslam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kammerlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kastner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutta","family":"Bergler-Klein FESC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Duca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"21779_CR1","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg, F. L., Grogan, M., Hanna, M., Kelly, J. W. & Maurer, M. S. Transthyretin amyloid cardiomyopathy: JACC State-of-the-Art review. J. Am. Coll. Cardiol. 73, 2872\u20132891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"21779_CR2","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore, J. D. et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 133, 2404\u20132412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612 (2016).","journal-title":"Circulation"},{"key":"21779_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMOA1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer, M. S. et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl. J. Med. 379, 1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMOA1805689 (2018).","journal-title":"N Engl. J. Med."},{"key":"21779_CR4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/CPT.3455","volume":"117","author":"A Michalon","year":"2024","unstructured":"Michalon, A. et al. Prediction of cardiac ATTR depletion by NI006 (ALXN2220) using mechanistic PK\/PD modeling. Clin. Pharmacol. Ther. 117, 261. https:\/\/doi.org\/10.1002\/CPT.3455 (2024).","journal-title":"Clin. Pharmacol. Ther."},{"key":"21779_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMOA2305434","volume":"390","author":"JD Gillmore","year":"2024","unstructured":"Gillmore, J. D. et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl. J. Med. 390, 132\u2013142. https:\/\/doi.org\/10.1056\/NEJMOA2305434 (2024).","journal-title":"N Engl. J. Med."},{"key":"21779_CR6","doi-asserted-by":"publisher","unstructured":"Fontana, M. et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. N Engl. J. Med. 392. https:\/\/doi.org\/10.1056\/NEJMOA2409134 (2025).","DOI":"10.1056\/NEJMOA2409134"},{"key":"21779_CR7","doi-asserted-by":"publisher","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","volume":"15","author":"P Elliott","year":"2022","unstructured":"Elliott, P. et al. Long-Term survival with Tafamidis in patients with transthyretin amyloid cardiomyopathy. Circ. Heart Fail. 15, e008193. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.120.008193 (2022).","journal-title":"Circ. Heart Fail."},{"key":"21779_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/EURHEARTJ\/EHAD194","author":"E Arbelo","year":"2023","unstructured":"Arbelo, E. et al. 2023 ESC guidelines for the management of cardiomyopathies developed by the task force on the management of cardiomyopathies of the European society of cardiology (ESC). Eur. Heart J. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD194 (2023).","journal-title":"Eur. Heart J."},{"key":"21779_CR9","unstructured":"Search for clinical trials - EMA n. d. accessed January 17, (2025). https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2024-514434-20-00"},{"key":"21779_CR10","unstructured":"Search for clinical trials - EMA n. d. accessed January 17, (2025). https:\/\/euclinicaltrials.eu\/search-for-clinical-trials\/?lang=en&EUCT=2023-506669-70-00"},{"key":"21779_CR11","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.cardfail.2024.02.014","volume":"30","author":"N Chan","year":"2024","unstructured":"Chan, N. et al. Temporal outcomes of patients diagnosed with transthyretin cardiac amyloidosis. J. Card Fail. 30, 1100\u20131107. https:\/\/doi.org\/10.1016\/j.cardfail.2024.02.014 (2024).","journal-title":"J. Card Fail."},{"key":"21779_CR12","doi-asserted-by":"publisher","unstructured":"Porcari, A. et al. Clinical phenotype and prognosis of asymptomatic patients with transthyretin cardiac amyloid infiltration. JAMA Cardiol. 10 https:\/\/doi.org\/10.1001\/JAMACARDIO.2024.5221 (2025).","DOI":"10.1001\/JAMACARDIO.2024.5221"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21779-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21779-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21779-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:49:29Z","timestamp":1761752969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-21779-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["21779"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-21779-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.P.: Travel support from Alynlam; L.S. none; C.K. none; N.E. none; R.R. none; C.B. none; L.C.L. none; M.E. none; C.H. none; C.N. none; R.B.E. none; A.K. none; J.K. none; J.B.K. none; F.D.: Speaker fees and congress support from Bayer, Novartis, Alnylam, Pfizer, and AOP, as well as research grants from the Austrian Society of Cardiology and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37893"}}